FDA: Withdraw Belviq Weight-Loss Drug Due To Increased Cancer In Study Subjects
SILVER SPRING, Md. — The Food and Drug Administration on Feb. 13 said it has asked Eisai Co. Ltd. to voluntarily withdraw the company’s Belviq and Belviq XR prescription weight loss...To view the full article, register now.
Already a subscriber? Click here to view full article